Infergen Related Published Studies
Well-designed clinical trials related to Infergen (Interferon Alfacon-1)
U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients. [2011.03]
Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial. [2009.07.09]
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. [2009.06]
Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1). [2009.05]
Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. [2007.06]
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. [2006.11.14]
Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. [2005.04]
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. [2003.11]
The safety and tolerability of daily infergen plus ribavirin in the treatment of naiive chronic hepatitis C patients. [2003.01]
A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lymphoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. [2002.01]
Efficacy of consensus interferon in the treatment of chronic hepatitis C. [2000.12]
A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection. [2000.10]
Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C. Consensus Interferon Study Group. [1999.12]
Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. [1999.12]
A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C. [1999.09]
Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. [1999.08]
Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. [1999.07]
A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. Consensus Interferon Study Group. [1999.03]
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy.The Consensus Interferon Study Group. [1999.01]
Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. [1998.11]
Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. [1997.09]
Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. [1997.09]
Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b. [1992.04]
Well-designed clinical trials possibly related to Infergen (Interferon Alfacon-1)
Medical treatment of viral pneumonia including SARS in immunocompetent adult. [2004.11]
Other research related to Infergen (Interferon Alfacon-1)
Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. [2011.08]
U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin
for "difficult-to-treat" HCV genotype 1 patients. [2011]
Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. [2010.11]
Elevated hepatic transaminases associated with the use of interferon alfacon-1 and ribavirin. [2009.03.01]
[Case of ANCA associated vasculitis induced by interferon therapy for HCV infection] [2008.12]
Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy. [2008.09]
Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. [2008.06.20]
Sudden onset of diabetic ketoacidosis during consensus interferon therapy for chronic viral hepatitis C. [2008.04]
Maillard reaction products in the Escherichia coli-derived therapeutic protein interferon alfacon-1. [2008.04]
Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. [2008.03]
Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model. [2007.04.10]
Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. [2007.02]
Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. [2007.01.28]
Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C. [2007]
Cyto-reduction of neuroendocrine tumours using Sandostatin LAR in combination with Infergen: results of a case series. [2006.12]
Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy. [2006.05]
Daily consensus interferon (CIFN) monotherapy in non-responders or relapsers to a previous interferon regime: one year follow-up after 48 weeks of treatment. [2006.03]
Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. [2006]
[Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C] [2006]
Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. [2005.06]
Cutaneous mucinosis and skin necrosis complicates interferon alfacon-1 (consensus interferon) treatment of chronic hepatitis C. [2005.02.28]
Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids. [2005]
Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo. [2004.11.01]
Immune thrombocytopenic purpura in a patient treated with interferon alfacon-1. [2004.09]
Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. [2004.08]
Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. [2004.03]
Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. [2003.12.24]
Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. [2003.12]
High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. [2003.08]
[Interferon-alpha treatment of the Churg-Strauss syndrome] [2003.07.04]
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. [2003.04]
A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. [2003.04]
[Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile] [2002.12]
Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. [2002.07]
Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. [2002.05]
Genetically modified interferon: is there a consensus yet? [2002.05]
High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study. [2002]
An analysis of acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon. [2001.12]
Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons. [2001]
Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. [2001]
Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha. [2000.01]
Treatment of chronic hepatitis C: comparative virologic response rates among the different interferons. [1999]
Other possibly related research studies
Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. [2005.08]
Modeling hamsters for evaluating West Nile virus therapies. [2004.07]
First phase hepatitis c viral kinetics in previous nonresponders patients. [2003.01]
Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1. [2002.05]
Induction of indoleamine 2,3-dioxygenase in vivo by IFN-con1. [2001.08]
Treatment options in patients with chronic hepatitis C. [2000.07]
Chronic hepatitis C: management of treatment failures. [2005.10]
Gateways to clinical trials. [2005.07]
Severe acute respiratory syndrome (SARS): the pharmacist's role. [2004.06]
[Pharmaceutical device of IFN] [2006.07]
Advances in gastrointestinal pharmacotherapy. [2005.12]
Gateways to clinical trials. [2006.12]
The management of coronavirus infections with particular reference to SARS. [2008.06.18]
The management of coronavirus infections with particular reference to SARS. [2008.09]
New opportunities for the management and therapy of hepatitis C in correctional settings. [2010.01]
|